Literature DB >> 15016723

Ligand-regulated internalization of the opioid receptor-like 1: a confocal study.

Maithé Corbani1, Christophe Gonindard, Jean-Claude Meunier.   

Abstract

To better understand opioid receptor-like 1 (ORL1) internalization, we fused the C terminus of ORL1, the nociceptin (noc) receptor, to the N terminus of a green fluorescent protein and used the fusion protein to characterize receptor endocytosis in live human embryonic kidney cells. The fusion altered neither the affinity of the receptor for noc or other ORL1 receptor ligands nor the ability of the receptor to mediate agonist-induced binding of GTPgamma(35)S, i.e. coupling with heterotrimeric G protein. Confocal microscopy showed that the fluorescent receptor was mostly associated (>75%) with the periplasmic membrane. In the presence of 0.1 microm noc, approximately 80% of receptors were internalized, and half-maximum internalization was reached in approximately 12 min at 22 C and approximately 6 min at 37 C. After washing, a normal receptor level was recovered within 70 min at 22 C. The lack of internalization in the presence of 0.45 m sucrose suggests that noc-induced receptor endocytosis mainly occurred via clathrin-coated pits. Coincubation of the recombinant cells with noc and tetramethylrhodamine-transferrin showed that ORL1 was mainly internalized through the endosome compartment. Lofentanil and Ro64-6198 ([(1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one]) promoted endocytosis of the fluorescent receptor as efficiently as noc. Among the two ORL1 receptor antagonists, J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one), but not III-BTD, blocked the noc-induced internalization of the fluorescent receptor. Two partial agonists were dramatically less efficient than noc to promote ORL1 internalization. They recruited very little (the pseudopeptide [Phe(1)psi(CH(2)-NH)Gly(2)]-noc-(1-13)NH(2)) or no (the hexapeptide Ac-Arg-Tyr-Tyr-Lys-Trp-Arg-NH(2)) G protein receptor kinase type 2 coupled to red fluorescent protein 1 at the membrane, suggesting that subsequent receptor phosphorylation necessary for internalization via coated pits is altered. Thus, partial agonists that induce a prolonged cell response without causing substantial receptor internalization may be good tools for further clinical treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016723     DOI: 10.1210/en.2004-0062

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  19 in total

1.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

Authors:  Maithé Corbani; Miguel Trueba; Stoytcho Stoev; Brigitte Murat; Julie Mion; Véra Boulay; Gilles Guillon; Maurice Manning
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

Review 2.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 3.  Signaling complexes of voltage-gated calcium channels.

Authors:  Ray W Turner; Dustin Anderson; Gerald W Zamponi
Journal:  Channels (Austin)       Date:  2011-09-01       Impact factor: 2.581

4.  Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels.

Authors:  Swetha S Murali; Ian A Napier; Beth K Rycroft; MacDonald J Christie
Journal:  J Physiol       Date:  2012-02-27       Impact factor: 5.182

5.  A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

Authors:  Linda M Rorick-Kehn; Roberto Ciccocioppo; Conrad J Wong; Jeffrey M Witkin; Maria A Martinez-Grau; Serena Stopponi; Benjamin L Adams; Jason S Katner; Kenneth W Perry; Miguel A Toledo; Nuria Diaz; Celia Lafuente; Alma Jiménez; Ana Benito; Concepción Pedregal; Friedbert Weiss; Michael A Statnick
Journal:  Alcohol Clin Exp Res       Date:  2016-04-16       Impact factor: 3.455

6.  NOP receptor antagonism reduces alcohol drinking in male and female rats through mechanisms involving the central amygdala and ventral tegmental area.

Authors:  Anna Maria Borruto; Yannick Fotio; Serena Stopponi; Gloria Brunori; Michele Petrella; Francesca Felicia Caputi; Patrizia Romualdi; Sanzio Candeletti; Rajesh Narendran; Linda M Rorick-Kehn; Massimo Ubaldi; Friedbert Weiss; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

7.  Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.

Authors:  Jean Claude Reubi; Judit Erchegyi; Renzo Cescato; Beatrice Waser; Jean E Rivier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-16       Impact factor: 9.236

8.  Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor.

Authors:  Steven D Chang; S Wayne Mascarella; Skylar M Spangler; Vsevolod V Gurevich; Hernan A Navarro; F Ivy Carroll; Michael R Bruchas
Journal:  Mol Pharmacol       Date:  2015-07-01       Impact factor: 4.436

9.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.